China's 11th Bulk Drug Procurement Covers 55 Chronic Disease Medicines

By the end of March 2026, China's 11th centralized drug procurement program has been fully implemented nationwide, covering 55 essential medicines for chronic diseases such as hypertension and diabetes. The average price reduction reached 58%, with strict controls capping markup rates at 15%. This policy mandates all designated pharmacies to maintain full stock without shortages, reshaping supply chain dynamics for domestic and international stakeholders.

Event Overview

The 11th round of China's bulk drug procurement program achieved nationwide coverage of 55 chronic disease medications by March 2026. Key confirmed facts include:

• Average price reduction of 58% across all included drugs
• Maximum 15% markup rate enforced for pharmacies
• Mandatory full inventory compliance for all designated pharmacies

Impact on Sub-sectors

API Exporters

Chinese API manufacturers face intensified cost pressure, potentially affecting export pricing stability. Overseas buyers should monitor GMP compliance upgrades as suppliers adapt to domestic procurement standards.

Formulation Contract Manufacturers

OEM/ODM providers must demonstrate enhanced production flexibility to meet both volume guarantees and export commitments. Delivery reliability becomes a critical differentiator.

International Procurement Agencies

Bulk buyers gain a transparent window to evaluate Chinese suppliers' cost competitiveness and quality consistency under regulated pricing conditions.

Key Focus Areas

Supply Chain Audits

International buyers should verify suppliers' dual-capacity management systems for handling domestic procurement volumes while maintaining export commitments.

Quality Documentation

Request updated GMP certification and batch traceability records as Chinese manufacturers upgrade systems to meet new compliance requirements.

Contract Renegotiation

Anticipate potential price adjustment clauses from suppliers affected by domestic procurement pricing, particularly for crossover chronic disease APIs.

Industry Observation

Analysis suggests this procurement round serves as both a market reshuffling mechanism and an indirect quality benchmark for China's pharmaceutical exports. The enforced production discipline creates observable metrics for international partners assessing supplier reliability. Current data indicates this policy has transitioned from pilot phase to full implementation, with measurable impacts on manufacturer operations.

Conclusion

This procurement implementation provides concrete operational data points for evaluating Chinese chronic disease drug suppliers. International stakeholders should interpret this as a stabilization signal rather than market disruption, with documented compliance and production metrics now available for due diligence.

Sources

• China National Healthcare Security Administration procurement bulletin
• Implementation notices from provincial medical insurance bureaus